President Donald Trump's plan to impose 100% tariffs on pharmaceuticals may have a smaller effect than originally anticipated due to certain loopholes, although the pharmaceutical industry, notably Big Pharma, remains dissatisfied. Trump's investigation under Section 232 to evaluate whether medical products from China, Vietnam, and Malaysia are a national security threat has resulted in the proposed tariffs. This is likely to impact U.S. consumers and exporters in these nations. Oxford Economics' analyst Louise Loo forecasts that the drug tariffs will significantly impact American consumers. The news has caused a downturn in Asian markets, though some U.S. pharmaceutical companies such as Pfizer, Eli Lilly, and Bristol-Myers Squibb have seen a boost in premarket shares.